



News Release

July 30, 2026

EIKEN CHEMICAL CO., LTD.

Representative: Yuji Segawa, President and CEO

Securities code: 4549 [TSE Prime Market]

Collaboration Agreement with TAUNS Laboratories, Inc. for the Sales of POCT Products

— Strengthening Sales Channels in the Domestic Clinic Market —

EIKEN CHEMICAL CO., LTD. (Head Office: Chiyoda-ku, Tokyo; hereinafter "the Company") hereby announces that it has entered into a collaboration agreement with TAUNS Laboratories, Inc. (Head Office: Izunokuni-shi, Shizuoka; hereinafter "TAUNS") to strengthen sales of the Company's POCT products in the clinic market.

Through this collaboration, the Company will expand the presence of its products in the clinic market by leveraging TAUNS' sales network.

Background and Purpose of the Collaboration

Under "Management Plan 2030", the Company has identified strengthening the profitability of its domestic business as a key strategic priority and is actively expanding its POCT product offerings in the clinic market in response to growing demand for rapid diagnostic testing.

TAUNS has established a broad sales platform in the field of infectious disease diagnostics. By combining EIKEN's product quality and development capabilities with TAUNS' extensive sales network, both companies expect to accelerate the adoption of the target products and have therefore agreed to this collaboration.

Overview of the Collaboration

This collaboration covers three in vitro diagnostic products manufactured and marketed by EIKEN, including IMMUNOCATCH®-Adeno and IMMUNOCATCH®-Strep A.

The companies are preparing a framework under which EIKEN will supply the products and TAUNS will be responsible for sales in the domestic clinic market, with commercial launch scheduled for this autumn.

About the Target Products

IMMUNOCATCH®-Adeno and IMMUNOCATCH®-Strep A are in vitro diagnostic reagents designed for the rapid detection of adenovirus antigens or Group A β -hemolytic streptococcal antigens from specimens such as throat swabs.

These products simplify testing procedures by eliminating the need for extraction solution preparation and waiting periods. In addition, both products utilize a common extraction solution and standardized operating procedures. By enabling testing for both infections using a single specimen and providing results in approximately five minutes, the products support faster and more efficient diagnosis in clinical settings.

Outlook

Through this collaboration, the Company aims to expand the adoption of its POCT products in the clinic market and contribute to more rapid and appropriate diagnosis across a broader range of healthcare settings.

Guided by its management philosophy, "Protect the health of people through healthcare", the Company will continue working to sustainably enhance corporate value by delivering meaningful value to healthcare professionals and patients.

The impact of this collaboration has been incorporated into the Company's consolidated earnings forecast for the current fiscal year.

Contact details

Sustainability Department

Eiken Chemical Co., Ltd.

TEL: +81-3-5846-3305, e-mail: koho@eiken.co.jp

<https://www.eiken.co.jp/en>